SNO 2019: Infigratinib Demonstrates Improvement in One-Third of FGFR-Altered Glioblastomas and/or Gliomas
Combinations in patients with proven FGFR-TACC fusion genes are being explored as well.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.